A Review of Sars-Cov-2 Pharmacotherapy | Chapter 18 | Clinical Manifestations of Covid-19: A Multi-Disciplinary Approach

 

The Coronavirus viral disease 2019 (COVID-19) is arguably the most important medical and public health challenge of the current decade. This has resulted in tens of millions of deaths and disturbed socio-economic lives across the globe.  Clinicians and scientists have been assessing many potential anti-virals for effective control of SARS-CoV-2. Many drugs have been repurposed and granted emergency authorization for use in the treatment of COVID-19 cases. Some of the drugs that have been assessed include Remdesivir, Ribavirine, Favipiravir, Lopinavir/ritonavir, hydroxychloroquine, dexamethasone, biologics and the anti-parasitic ivermectin. Dexamethasone significantly cut mortality among severe and critical SARS-CoV-2 cases. There were no clinical benefits with the use of hydroxychloroquine and Lopinavir/ritonavir in the RECOVERY Trials. Early observational studies and a randomized controlled clinical trial conducted in Nigeria demonstrated the possibility of the efficacy of ivermectin in the treatment of SARSCoV-2. Overall, effective and efficient pharmacotherapeutic interventions will be important in achieving SARS-CoV-2 control. There is also evidence that the COVID-19 vaccine was effective in curtailing the effects of the pandemic. Different generic vaccines available are DNA vaccine, mRNA vaccine, and non-replicating viral vector vaccines

 

Author(s) Details:

 

Olumuyiwa Elijah Ariyo
Infectious Diseases & Tropical Medicine Unit, Department of Medicine, Faculty of Clinical Sciences, College of Medicine and Health Sciences, Afe Babalola University Ado-Ekiti, Ekiti State/Federal Teaching Hospital, Ido-Ekiti, Nigeria.

 

Joshua Gini
Stroke Medicine United Lincolnshire Hospital, Lincoln County Hospital, United Kingdom.

 

Oladipo Vincent Akinmade
USAID Integrated Health Program Abakaliki, Ebonyi State, Nigeria.

 

Ugochukwu Anthony Eze
Department of Ophthalmology, Federal Medical Centre, Asaba, Nigeria and Honorary Supervisor University of Edinburgh Masters of Surgery Program in Clinical Ophthalmology, United Kingdom

 

Please see the book here:  https://doi.org/10.9734/bpi/mono/978-81-973195-5-6/CH18